G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 100.6 INR -2.89% Market Closed
Market Cap: 134.9B INR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

GLS Price Targets Summary
Glenmark Life Sciences Ltd

Wall Street analysts forecast GLS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLS is 1 214.41 INR with a low forecast of 797.9 INR and a high forecast of 1 428 INR.

GLS Lowest Forecast
Wall Street Target
797.9 INR
28% Downside
GLS Average Forecast
Wall Street Target
1 214.41 INR
10% Upside
GLS Highest Forecast
Wall Street Target
1 428 INR
30% Upside
Lowest
Price Target
797.9 INR
28% Downside
Average
Price Target
1 214.41 INR
10% Upside
Highest
Price Target
1 428 INR
30% Upside
Glenmark Life Sciences Ltd Competitors:
Price Targets
BMY
Bristol-Myers Squibb Co
18% Upside
M
600993
Mayinglong Pharmaceutical Group Co Ltd
49% Upside
4746
Formosa Laboratories Inc
95% Upside
002422
Sichuan Kelun Pharmaceutical Co Ltd
22% Upside
BMY
Bristol-Myers Squibb Co
18% Upside
M
600993
Mayinglong Pharmaceutical Group Co Ltd
49% Upside
4746
Formosa Laboratories Inc
95% Upside
002422
Sichuan Kelun Pharmaceutical Co Ltd
22% Upside
D
DHG
Dhg Pharmaceutical Joint-Stock Co
5% Upside
NEU
Neuren Pharmaceuticals Ltd
116% Upside
C
300765
CSPC Innovation Pharmaceutical Co Ltd
20% Upside
XERS
Xeris Biopharma Holdings Inc
37% Upside

Revenue
Forecast

Revenue Estimate
Glenmark Life Sciences Ltd

For the last 4 years the compound annual growth rate for Glenmark Life Sciences Ltd's revenue is 10%. The projected CAGR for the next 3 years is 12%.

10%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Glenmark Life Sciences Ltd

For the last 4 years the compound annual growth rate for Glenmark Life Sciences Ltd's operating income is 9%. The projected CAGR for the next 3 years is 12%.

9%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Glenmark Life Sciences Ltd

For the last 4 years the compound annual growth rate for Glenmark Life Sciences Ltd's net income is 11%. The projected CAGR for the next 3 years is 15%.

11%
Past Growth
15%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

See Also

Summary
GLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLS stock valuation using valuation multiples.
Wall Street Estimates
GLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GLS's stock price target?
Price Target
1 214.41 INR

According to Wall Street analysts, the average 1-year price target for GLS is 1 214.41 INR with a low forecast of 797.9 INR and a high forecast of 1 428 INR.

What is Glenmark Life Sciences Ltd's Revenue forecast?
Projected CAGR
12%

For the last 4 years the compound annual growth rate for Glenmark Life Sciences Ltd's revenue is 10%. The projected CAGR for the next 3 years is 12%.

What is Glenmark Life Sciences Ltd's Operating Income forecast?
Projected CAGR
12%

For the last 4 years the compound annual growth rate for Glenmark Life Sciences Ltd's operating income is 9%. The projected CAGR for the next 3 years is 12%.

What is Glenmark Life Sciences Ltd's Net Income forecast?
Projected CAGR
15%

For the last 4 years the compound annual growth rate for Glenmark Life Sciences Ltd's net income is 11%. The projected CAGR for the next 3 years is 15%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 252,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.